27
Feb

After 25 years at the helm of one of biotech’s best-case scenarios, Regeneron CEO Leonard Schleifer has crossed the $1 billion threshold, according to Forbes, thanks largely to the company’s blockbuster eye drug. And, with a stable of promising late-stage treatments waiting in the wings, the Tarrytown, NY, executive’s most profitable work may still be ahead of him.

…read more

Source: Regeneron’s Schleifer hits the $1B mark, but his biotech is just getting started

    

0 No comments